Published in Oncogene on March 11, 2013
AXL kinase as a novel target for cancer therapy. Oncotarget (2014) 1.14
Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion. Mol Cell Biol (2014) 1.02
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clin Cancer Res (2016) 1.00
Axl as a mediator of cellular growth and survival. Oncotarget (2014) 0.99
Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol (2014) 0.95
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res (2015) 0.87
Advances in targeted therapies and new promising targets in esophageal cancer. Oncotarget (2015) 0.87
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling. Theranostics (2016) 0.87
AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Mol Cancer Res (2016) 0.83
AXL is an oncotarget in human colorectal cancer. Oncotarget (2015) 0.82
The NF-κB Pathway and Cancer Stem Cells. Cells (2016) 0.82
Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion. Oncogene (2015) 0.81
ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program. Cancer Res (2015) 0.80
Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Mol Biol Cell (2015) 0.80
Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma. PLoS One (2014) 0.80
Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer. Oncogene (2016) 0.79
MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells. Oncotarget (2016) 0.78
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget (2015) 0.78
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo. Oncotarget (2016) 0.78
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. J Thorac Oncol (2016) 0.78
Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget (2015) 0.78
Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells. Oncogenesis (2016) 0.77
Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer (2017) 0.77
Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer. Oncotarget (2016) 0.77
Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer. Oncoscience (2015) 0.77
The quorum sensing peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro. PLoS One (2015) 0.76
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. PLoS One (2016) 0.76
AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget (2016) 0.76
Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells. Evid Based Complement Alternat Med (2016) 0.75
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Curr Oncol Rep (2017) 0.75
The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells. Mol Cancer (2017) 0.75
Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. Oncotarget (2017) 0.75
The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel) (2016) 0.75
3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway. Sci Rep (2016) 0.75
Biomarkers for EMT and MET in breast cancer: An update. Oncol Lett (2016) 0.75
Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Sci Rep (2017) 0.75
n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma. Int J Mol Sci (2017) 0.75
Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival. Oncotarget (2017) 0.75
Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype. Lab Invest (2017) 0.75
HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling. Oncotarget (2017) 0.75
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol (1991) 3.57
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A (2009) 3.29
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res (2009) 3.10
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene (2010) 3.05
Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res (2008) 2.96
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res (2010) 2.87
Cancer stem cells--old concepts, new insights. Cell Death Differ (2008) 2.56
Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J (2006) 2.49
Epithelial-mesenchymal transition. J Cell Sci (2005) 2.39
Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.38
Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A (2006) 2.30
Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.22
Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A (2006) 2.05
Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia (2005) 2.04
AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res (2008) 2.01
Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene (2009) 2.01
Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res (2006) 1.84
The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther (2009) 1.78
Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther (2010) 1.69
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res (2011) 1.65
Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene (2008) 1.55
AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res (2010) 1.50
The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest (2008) 1.47
Akt is a downstream target of NF-kappa B. J Biol Chem (2002) 1.43
Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem (2009) 1.41
Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer (1995) 1.41
Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis (2003) 1.32
Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res (2004) 1.32
Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer (2010) 1.28
NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed) (2011) 1.19
Breast cancer progression: controversies and consensus in the molecular mechanisms of metastasis and EMT. J Mammary Gland Biol Neoplasia (2007) 1.18
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol (2009) 1.14
Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol (2003) 1.12
Tumor initiating cancer stem cells from human breast cancer cell lines. Int J Oncol (2009) 1.04
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer (2009) 0.96
Axl-gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity. Mol Cell Biol (1999) 0.92
The evolution of cancer modeling: the shadow of stem cells. Dis Model Mech (2010) 0.91